UAE First to Approve Needle-Free Allergy Treatment

The UAE is proving that innovation doesn't have to move at a snail's pace when lives are on the line.

The country's Emirates Drug Establishment just approved Baxfendy, making the UAE the first nation worldwide to offer AstraZeneca's new hypertension treatment. Unlike older blood pressure medications that manage symptoms, this one targets the root cause by blocking aldosterone production, the hormone that can drive uncontrolled high blood pressure.

But that's just one breakthrough in a remarkable year for UAE healthcare. The country also approved Neffy, the world's first needle-free epinephrine nasal spray for severe allergic reactions. For the 30 million people who carry EpiPens for life-threatening anaphylaxis, this nasal spray offers a needle-free alternative that could save lives during moments of panic.

Abu Dhabi took things further by introducing Foundayo, a daily oral obesity treatment integrated into a comprehensive weight management program. The UAE became only the second country globally after the United States to approve this medication, pairing it with behavioral support and digital monitoring for personalized care.

The approvals keep coming. In 2025 alone, the UAE greenlit treatments for immune disorders, progressive multiple sclerosis, spinal muscular atrophy, and sickle cell disease. The country also became the first destination outside America to offer Tremfya for ulcerative colitis and Crohn's disease.

This speed isn't reckless. It's strategic. During COVID-19, the UAE became the first country worldwide to grant emergency authorization for monoclonal antibody treatments while developing stem cell therapies. The nation also moved quickly on Aduhelm for early Alzheimer's disease, becoming the second country globally to approve it.

The Ripple Effect

When one country speeds up access to breakthrough medicines, it creates pressure on regulatory agencies worldwide to move faster. Patients in other nations see what's possible and demand the same urgency from their own healthcare systems.

The UAE's approach shows that rigorous safety standards and rapid approvals aren't opposites. By investing in medical innovation infrastructure and streamlined review processes, countries can deliver hope to patients years earlier than traditional timelines allow.

For people living with chronic conditions that have few treatment options, geography increasingly determines access to cutting-edge care. The UAE is showing the world what happens when a nation decides that patients shouldn't have to wait.

Thousands of people with high blood pressure, severe allergies, and obesity now have access to treatments that didn't exist for them just months ago.